All In Biotech

Drug Trial Radar · NCT07659782

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Jul 22, 2026

Primary completion

Jun 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Verastem, Inc.Industry
Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of VS-7375 alone in patients with metastatic KRAS G12D-mutated Non-Small Cell Lung Cancer

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • VS-7375Drug

    Taken by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1Time frame: 6 months
  2. To characterize the safety and tolerability of VS-7375 monotherapy administered on a daily oral schedule in participants with KRAS G12D-mutated NSCLCTime frame: 6 months

Locations

26 sites in 4 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona · Recruiting

  • START LA

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • University of Colorado Cancer Center

    Aurora, Colorado · Recruiting

  • BRCR Global - Coral Springs

    Coral Springs, Florida · Recruiting

  • BRCR Global- Tamarac

    Tamarac, Florida · Recruiting

  • Moffit Cancer Centre

    Tampa, Florida · Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • START New Jersey

    East Brunswick, New Jersey · Recruiting

  • NYU

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • START Fort Worth

    Fort Worth, Texas · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Macquarie University Hospital

    Sydney, New South Wales, Australia · Recruiting

  • ICON Cancer Centre South Brisbane

    Brisbane, Queensland, Australia · Recruiting

  • Monash Health

    Clayton, Victoria, Australia · Recruiting

  • CHU UCL Namur - Sainte-Elisabeth

    Namur, Belgium · Recruiting

  • BRCR Global- San Juan

    San Juan, Puerto Rico · Recruiting

  • BRCR Global- Yauco

    Yauco, Puerto Rico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.